Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Improved survival associated with ibrutinib compared to chemotherapy in MCL with CNS relapse

Carlo Visco • 14 Jun 2023
ICML 2023
CNS Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma BTK inhibitors Ibrutinib

Carlo Visco, MD, University of Verona, Verona, Italy, discusses the results of a study which compared the outcomes of patients with mantle cell lymphoma (MCL) and central nervous system (CNS) relapse treated with ibrutinib versus chemoimmunotherapy. Patients treated with ibrutinib demonstrated an improvement in progression-free survival (PFS), and Dr Visco further comments on the importance of developing novel agents for this difficult-to-treat population. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Carlo Visco

2:26
LATE-POD study: ibrutinib improves PFS in younger patients with R/R MCL experiencing late relapse
Carlo Visco • 14 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals